Biotech Values

[ghmm]

Immuno-Oncology:

I don't have a list and not sure if this qualifies as fringe but I have been long Nektar for a while now and their immunotherapy program is pretty under the radar (of course their 1.5B market cap doesn't make it a pure play here). They have used their PEG technology in pretty creative ways to develop some pipeline candidates. Their Immuno-oncology is very early though.

NKTR-214 which targets IL-2 is finally going into patients.
http://finance.yahoo.com/news/nektar-md-anderson-cancer-center-120000043.html

Here is a poster from last years ASCO (preclinical) combining with Checkpoint inhibitors or anti-PD-1 agents.
http://www.nektar.com/pdf/pipeline/NKTR-214/NKTR-214_ASCO_Poster_2014.pdf

They mentioned 2 other pre-clinical programs that they said they would talk about at their R&D Day (10/8)
NKTR-255 (IL-15 Cancer Immunotherapy)
NKTR-218 (IDO Inhibitor)

I have been long the stock for a couple years and recently bought more thinking their royalty revenue potential represents good value even at current prices and then you have a potential big opportunity if NKTR-181 hits (it failed Phase 2 but they went ahead into P3 with a modified trial) and the under the radar Oncology assets especially now that 102 isn't priced in. I think NKTR-214 is really interesting if they really got the toxicity issue around IL-2 reduced.
This is the slide deck from the jeffereies conference:
http://files.shareholder.com/downloads/NKTR/0x0x833274/536E44DF-E108-4C26-B9FC-39D57C2EDA9E/FINAL_JEFFERIES_NKTR_Presentation-06022015.pdf

And here are the links to the webcast:
http://wsw.com/webcast/jeff88/nktr/
http://wsw.com/webcast/jeff88/nktr.bo/ (break out session)

I would be very interested in hearing others opinion.